Signadori Bio, a preclinical-stage biopharmaceutical company developing a next generation, off-the shelf, in vivo engineered, monocyte immunotherapy platform to treat solid tumors, has appointed Dr. Selwyn Ho as Chief Executive Officer. Ho is an experienced biopharma and biotech executive, with nearly 30 years of experience across commercialization, drug development and multiple pre-& post-product launches, with a focus in ophthalmology, immunology and immuno-oncology, leveraging cell the...